FTC suit accuses AbbVie, Teva of pay-for-delay scheme
This article was originally published in Scrip
Executive Summary
The Federal Trade Commission (FTC) on 8 September revealed it was suing AbbVie and Teva alleging the firms entered into a anticompetitive pay-for-delay scheme involving the testosterone replacement therapies (TRTs) of the former firm's AndroGel, which has about $1bn in annual sales.